NCT06976983Not yet recruiting
Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
Effects of Transcranial Static Magnetic Stimulation (tSMS) in the Treatment of Hyperkinetic Symptoms of Huntington's Disease
Source: ClinicalTrials.gov · Last updated 16 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recurrent, unpredictable and non-rhythmic movements of the trunk, face and limbs. Non-invasive brain neuromodulation has been proposed as a possible treatment for involuntary movements in several clinical conditions including HD. The objective of the study is to evaluate the effect of home treatment with repeated sessions of transcranial static magnetic field stimulation (tSMS) in safely reducing choreic hyperkinesis in HD patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Nov 2024
- Start date
- 1 Sept 2025
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Neuromed IRCCS
- Diseases
- Huntington's disease
- NCT number
- NCT06976983
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Sept 2025 to the primary completion date, 30 Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received an investigational drug in a clinical trial within 30 days of the baseline visit or have planned to use such an investigational drug during the study
Other
- Contraindications to exposure to magnetic fields
- Patients who are pregnant or breastfeeding
- Presence of significant risk of suicidal behavior
Who the study is looking for
- Diagnosis of HD genetically confirmed (number of CAG triplets ≥36)
- Presence of chorea movements quantified with a score ≥ 10 on the sum of the scores of the subscale of the Unified Huntington's Disease Rating Scale (UHDRS) for the evaluation of maximum chorea for the facial, oro-bucco-lingual, truncal, four limbs districts
- Ability to provide written informed consent
- No changes in drug therapy in the 8 weeks prior to the baseline visit
- No changes in drug therapy for the entire duration of the study
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.